Date Title
May 24, 2018
Realm Therapeutics - Enrollment complete for Phase 2 study of PR022
RNS Number : 1054P Realm Therapeutics PLC 24 May 2018   Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis   Company Further Strengthens IP Portfolio with New USPTO Notice of Allowance   Reiterates Plans to File an Initial New Drug (IND) Application for PR022 in
May 23, 2018
Realm Therapeutics - Filing with US SEC to Facilitate Nasdaq Listing
RNS Number : 9552O Realm Therapeutics PLC 23 May 2018   Realm Therapeutics Publicly Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares   MALVERN, PA ,   May 23, 2018 - Realm Therapeutics plc (AIM: RLM) (the Company or Realm), a clinical
May 21, 2018
Realm Therapeutics - Data Presentation at IID 2018
RNS Number : 6495O Realm Therapeutics PLC 21 May 2018     Realm Therapeutics Presents Data Highlighting its Proprietary Immunomodulatory Technology's Potential in Acne and Psoriasis at IID 2018     MALVERN, PA , May 21, 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical
May 2, 2018
Realm Therapeutics - Annual Financial Report Available
RNS Number : 9097M Realm Therapeutics PLC 02 May 2018   Realm Therapeutics plc ("Realm Therapeutics" or the "Company")   Annual Report and Accounts Available   2 May 2018 -   Realm Therapeutics plc  (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics for
May 2, 2018
Realm Therapeutics - Realm Files Registration for Nasdaq Listing of ADS
RNS Number : 8259M Realm Therapeutics PLC 02 May 2018   THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION
May 2, 2018
Realm Therapeutics - Final Results
RNS Number : 8258M Realm Therapeutics PLC 02 May 2018   THIS ANNOUNCEMENT IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE
April 26, 2018
Realm Therapeutics - Notice of Results
RNS Number : 2760M Realm Therapeutics PLC 26 April 2018   Realm Therapeutics plc ("Realm Therapeutics", "Realm", or the "Company")   Notice of Full Year 2017 Results     April 26, 2018 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel
March 12, 2018
Realm Therapeutics - Second Price Monitoring Extn
RNS Number : 4711H Realm Therapeutics PLC 12 March 2018   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
March 12, 2018
Realm Therapeutics - Price Monitoring Extension
RNS Number : 4704H Realm Therapeutics PLC 12 March 2018   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders
March 12, 2018
Realm Therapeutics - Clinical Update including PR013 Phase II results
RNS Number : 3372H Realm Therapeutics PLC 12 March 2018   THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014   Realm Therapeutics Provides Clinical Update, including Results from a Phase 2 Study of PR013 in Allergic Conjunctivitis   MALVERN, PA ,
Displaying 11 - 20 of 26

Search Investor Relations